PNC Financial Services Group Inc. reduced its position in Omnicell, Inc. (NASDAQ:OMCL) by 16.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 42,294 shares of the company’s stock after selling 8,450 shares during the quarter. PNC Financial Services Group Inc. owned approximately 0.11% of Omnicell worth $3,043,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other large investors have also recently added to or reduced their stakes in the business. BlackRock Inc. increased its position in Omnicell by 14.1% in the second quarter. BlackRock Inc. now owns 5,575,352 shares of the company’s stock worth $292,428,000 after buying an additional 690,464 shares during the last quarter. Conestoga Capital Advisors LLC increased its position in Omnicell by 12.4% in the third quarter. Conestoga Capital Advisors LLC now owns 2,060,908 shares of the company’s stock worth $148,179,000 after buying an additional 227,685 shares during the last quarter. Janus Henderson Group PLC increased its position in Omnicell by 9.8% in the third quarter. Janus Henderson Group PLC now owns 1,662,720 shares of the company’s stock worth $119,550,000 after buying an additional 148,741 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Omnicell by 0.5% in the second quarter. Dimensional Fund Advisors LP now owns 1,547,072 shares of the company’s stock worth $81,144,000 after buying an additional 8,194 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in Omnicell by 2.5% in the third quarter. Bank of New York Mellon Corp now owns 946,239 shares of the company’s stock worth $68,035,000 after buying an additional 22,890 shares during the last quarter.
In other news, Director James T. Judson sold 2,443 shares of the firm’s stock in a transaction on Thursday, November 1st. The stock was sold at an average price of $70.67, for a total value of $172,646.81. Following the completion of the transaction, the director now directly owns 24,952 shares of the company’s stock, valued at $1,763,357.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Dan S. Johnston sold 6,250 shares of the firm’s stock in a transaction on Monday, October 15th. The stock was sold at an average price of $63.47, for a total value of $396,687.50. Following the completion of the transaction, the executive vice president now directly owns 35,996 shares of the company’s stock, valued at $2,284,666.12. The disclosure for this sale can be found here. Insiders sold 19,267 shares of company stock valued at $1,309,116 over the last ninety days. Corporate insiders own 3.71% of the company’s stock.
Omnicell stock opened at $69.83 on Friday. Omnicell, Inc. has a one year low of $39.75 and a one year high of $79.48. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.78 and a quick ratio of 1.32. The firm has a market capitalization of $2.80 billion, a PE ratio of 387.94, a P/E/G ratio of 4.22 and a beta of 0.99.
Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Thursday, October 25th. The company reported $0.49 EPS for the quarter, topping the Zacks’ consensus estimate of $0.40 by $0.09. Omnicell had a return on equity of 7.91% and a net margin of 6.11%. The firm had revenue of $204.27 million during the quarter, compared to analyst estimates of $203.48 million. Analysts anticipate that Omnicell, Inc. will post 1.42 EPS for the current fiscal year.
A number of analysts have issued reports on OMCL shares. Benchmark raised their target price on Omnicell from $66.00 to $79.00 and gave the stock a “buy” rating in a research report on Friday, October 5th. BidaskClub downgraded Omnicell from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 4th. Craig Hallum raised their target price on Omnicell from $65.00 to $80.00 and gave the stock a “buy” rating in a research report on Monday, September 17th. Zacks Investment Research raised Omnicell from a “sell” rating to a “hold” rating in a report on Monday, August 13th. Finally, MED raised their price target on Omnicell from $59.00 to $71.00 and gave the stock an “in-line” rating in a report on Monday, October 22nd. Three investment analysts have rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $72.13.
ILLEGAL ACTIVITY WARNING: “PNC Financial Services Group Inc. Sells 8,450 Shares of Omnicell, Inc. (OMCL)” was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/12/08/pnc-financial-services-group-inc-sells-8450-shares-of-omnicell-inc-omcl.html.
Omnicell, Inc provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications.
Featured Article: How to calculate the annual rate of depreciation
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.